Therapeutic compounds based on pyrazolopyridline derivatives

Details Therapeutic compounds based on pyrazolopyridline derivatives Therapeutic compounds based on pyrazolopyridline derivatives

2006-12-26

2006-12-26

Wilson, James O. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S275000, C544S316000, C544S331000

Reexamination Certificate

active

07153863

ABSTRACT:
The present invention provides compounds of formula (I):wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.

REFERENCES:
patent: 4576952 (1986-03-01), Hurst et al.
patent: 4621089 (1986-11-01), Ward et al.
patent: 4670432 (1987-06-01), Ward et al.
patent: 4985444 (1991-01-01), Shiokawa et al.
patent: 5155114 (1992-10-01), Shiokawa et al.
patent: 5204346 (1993-04-01), Shiokawa et al.
patent: 5234930 (1993-08-01), Shiokawa et al.
patent: 5296490 (1994-03-01), Shiokawa et al.
patent: 5300478 (1994-04-01), Michaely et al.
patent: 5498774 (1996-03-01), Mitsudera et al.
patent: 5552422 (1996-09-01), Gauthier et al.
patent: 5700816 (1997-12-01), Isakson et al.
patent: 5773530 (1998-06-01), Akahane et al.
patent: 5990148 (1999-11-01), Isakson et al.
patent: 6136839 (2000-10-01), Isakson et al.
patent: 6207675 (2001-03-01), Carry et al.
patent: 0 404 190 (1990-06-01), None
patent: 0 404 190 (1990-06-01), None
patent: 0 379 979 (1990-08-01), None
patent: 0 467 248 (1991-07-01), None
patent: 0 497 258 (1992-01-01), None
patent: 2 757 059 (1998-06-01), None
patent: EP 0 364 204 (1989-10-01), None
patent: WO 91 00092 (1991-01-01), None
patent: WO 91 19497 (1991-12-01), None
patent: WO 95 00501 (1995-01-01), None
patent: WO 96 06840 (1996-03-01), None
patent: WO 96 21667 (1996-07-01), None
patent: WO 96 31509 (1996-10-01), None
patent: WO 96 41626 (1996-12-01), None
patent: WO 96 41645 (1996-12-01), None
patent: WO 96 41625 (1997-12-01), None
patent: WO 98 56377 (1998-12-01), None
patent: WO 99 12930 (1999-03-01), None
patent: WO 99/58523 (1999-11-01), None
patent: WO 99/59585 (1999-11-01), None
patent: WO 99 64419 (1999-12-01), None
patent: WO 00/26216 (2000-05-01), None
patent: WO 00/52008 (2000-09-01), None
patent: WO 01/00615 (2001-01-01), None
patent: WO 01/014375 (2001-03-01), None
patent: WO 01 14375 (2001-03-01), None
patent: WO 02 16359 (2002-02-01), None
patent: WO 02 18382 (2002-03-01), None
patent: WO 02/48147 (2002-06-01), None
patent: WO 02 48147 (2002-06-01), None
patent: WO 02/048148 (2002-06-01), None
patent: WO 02/48148 (2002-06-01), None
patent: WO 02 066481 (2002-08-01), None
patent: WO 02/072581 (2002-09-01), None
patent: WO 03/00682 (2003-01-01), None
Wolft Manfréd E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G. S. et al, “Modern Pharmaceutices, 3ed. ”, Marcel Dekker, New York. 1996, pp. 451 and 596.
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 and 365.
Vippagunta et al., Advanced Drug Delivery Reviews 48: 3-26, 2001.
Bosseray et al., Pathol. Biol. (Paris) 50(8); 483-492, 2002.
Razonable et al., Herpes. 10(3): 60-65, 2003.
Vane, J. et al. “Towards a Better Aspirin.” Nature, vol. 367, Jan. 20, 1994, pp. 215-216.
Carter, J. et al. “Recently Reported Inhibitors of Cyclooxygenase-2.” Exp. Opin. Ther. Patents (1998), 8(1), pp. 21-29.
Talley, JJ., “Review, Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis, Selective Inhibitors of Cyclooxygenase-2.” Exp. Opin. Ther. Patents (1997) 7(1), pp. 55-62.
Roy, P., “A New Series of Selective Cox-2 Inhibitors: 5,6-Diarylthiazolo [3,2-b][1,22,4] Triazoles,”Bioorganiz&Med. Chem. Ltrs., vol. 7, No. 1, 1997, pp. 57-62.
Therien, Michael, Synthesis and Biological Evaluation of 5, 6-Diarylimidazo[2.1-b]Thiazole As Selective Cox-2 Inhibitors,Bioorganic&Med. Chem. Ltrs., vol. 7, No. 1, 1997, pp. 47-52.
Akahane, Atsushi, “Discovery of 6-Oxo-3-(2-Phenlypyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinebutanoic Acid (FR 838): A Novel Xanthine Adenosine A1Receptor Antagonist with Potent Diuretic Activity,”Journal of Medicinal Chemistry, vol. 42, No. 5, 1999, pp. 779-783.
Talley, John J., 5 Selective Inhibitors of Cyclooxygenase-2 (COX-2)Progress in Medicinal Chemistry, vol. 36, (1999): pp. 201-234.
Boehm, J.C., et al. “1-Substituted 4-Aryl-5-pyridinylimidazoles: A New Class of Cytokine Suppressive Drugs with Low 5-Lipoxygenase and Cyclooxygenase Inhibitory Potency.” J. Med. Chem. 1996, 39, pp. 3929-3937.
Hanson, G.J., et al. “Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis, Inhibitors of p38 kinase.” Expert Opinion Ther. Patents, 1997, 7(7):729-733.
Roizman, B., et al. “The Family Herpesviridae: A Brief Introduction.” Fields Virology, vol. 2, 4thEdition, pp. 2381-2397.
Douglas, R.G., Jr. “Introduction to Viral Diseases.” Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1739-1747, 1996.
Razonable, R.R., et al. “Herpes Virus Infections in Transplant Recipients: Current Challenges in the Clinical Management of Cytomegalovirus and Epstein-Barr Virus Infections.” PubMed Abstract, Herpes 10(3):60-5, Dec. 2003.
Bosseray; A., et al. “What's New in Vaccines Against Herpes Simplex Infections.” PubMed Abstract, Pathol. Biol (Paris) 50(*):483-92, Oct. 2002.
Sekine, T., et al. Cardioprotective Effects and Pluorescence Profiles of AHC-93, A Novel Dihydropyridine Compound with C1 Current Blocking Activity. Research Communications in Pharmacology and Toxicology, vol.-3, Nos. 1 & @, 1998, pp. 1-10.
Takahashi, M., et al. “Role of P-Glycoprotein in Human Natural Killer-Like Cell Line-Mediated Cytotoxicity.” Experimental Cell Research, 1999, vol. 253, pp. 396-402.

Affiliated with

Also associated with

Rating

Therapeutic compounds based on pyrazolopyridline derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic compounds based on pyrazolopyridline derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic compounds based on pyrazolopyridline derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3704360